Alpha Stem Cell Clinics Trials

The Alpha Stem Cell Clinics Network is pursuing its goal to accelerate the development and delivery of stem cell treatments to patients through high quality clinical trials. 

Browse the list of ongoing trials at Alpha Stem Cell Clinic locations in the table below. You can sort trials based on different fields by clicking on the appropriate column header. Trials are automatically listed by status of trial enrollment and Alpha Clinic location.

Alpha Clinic Trials

Alpha ClinicAlpha Clinic ContactTrial SponsorDisease IndicationClinical Trial NameStatus of EnrollmentLearn More
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas Active, not recruiting
City of Hope
Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org
City of Hope Cancer - Lymphoma (AIDS-Related) Gene Therapy After Frontline Chemotherapy in Treating Patients With AIDS-Related Non-Hodgkin Lymphoma Active, not recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/ II Dose Escalation Open Label Clinical Trial Evaluating the Safety and Efficacy of MAGE A10ᶜ⁷⁹⁶T in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Active, not recruiting
City of Hope
Warren Chow, MD
(626) 256-4673 x89200
wchow@coh.org
Adaptimmune Cancer - Sarcoma A Pilot Study of Genetically Engineered NY-ESO-1 Specific (c259) T Cells in HLA-A2+ Patients With Synovial Sarcoma Active, not recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 2 Multicenter Study Evaluating Subjects With Relapsed/Refractory Mantle Cell Lymphoma (ZUMA-2) Active, not recruiting
UCI & UC Davis
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu

UC Davis: Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Humacyte Kidney Failure An Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Renal Replacement Therapy: A Comparison With ePTFE Grafts as Conduits for Hemodialysis (HUMANITY) Active, not recruiting
UCLA & UCI
UCLA: Courtney Real, BSN
310-267-7433
creal@mednet.ucla.edu

UCI: UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
SanBio Brain Injury A Double-Blind, Controlled Phase 2 Study of the Safety and Efficacy of Modified Stem Cells (SB623) in Patients With Chronic Motor Deficit From Traumatic Brain Injury (TBI) Active, not recruiting
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
Orchard Therapeutics Severe Combined Immunodeficiency (SCID) Efficacy and Safety of a Cryopreserved Formulation of Autologous CD34+ Hematopoietic Stem Cells Transduced Ex Vivo With EFS Lentiviral Vector Encoding for Human ADA Gene in Subjects With ADA Deficiency Severe Combined Immunodeficiency Active, not recruiting
UCSD Viacyte Diabetes - Type 1 A Safety, Tolerability, and Efficacy Study of VC-01™ Combination Product in Subjects With Type I Diabetes Mellitus Active, not recruiting

UCSF
Cyrus Bascon
510-428-3885 ext 5396
CBascon@mail.cho.org
bluebird bio Sickle Cell Disease A Study Evaluating the Safety and Efficacy of the LentiGlobin BB305 Drug Product in Severe Sickle Cell Disease Active, not recruiting
UCSD
Barbara Parker, MD
858-822-6135
baparker@ucsd.edu

Rebecca Shatsky, MD
858-657-7000
rshatsky@ucsd.edu
UCSD Cancer - Breast Study of Cirmtuzumab and Paclitaxel for Metastatic or Locally Advanced, Unresectable Breast Cancer Active, not recruiting
UCSD
Teresa Rzesiewicz
844-317-7836
alphstemcellclinic@ucsd.edu
Discgenics Degenerative Disc Disease Study to Evaluate the Safety and Preliminary Efficacy of IDCT, a Treatment for Symptomatic Lumbar Intervertebral Disc Degeneration Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Longeveron Aging frailty Phase IIb Trial to Evaluate Longeveron Mesenchymal Stem Cells to Treat Aging Frailty Active, not recruiting
UCI & UCSD & UC Davis
UCI Stem Cell Clinic
949-824-3990
stemcell@uci.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Aivita Biomedical Cancer - Brain Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Newly Diagnosed Glioblastoma Active, not recruiting
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
Stratetech Burn wounds StrataGraft® Skin Tissue in the Promotion of Autologous Skin Regeneration of Complex Skin Defects Due to Thermal Burns That Contain Intact Dermal Elements Active, not recruiting
UCSF & UC Davis
Caleb Hwang
415-502-3498
Caleb.hwang@ucsf.edu

Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Poseida Therapeutics, Inc. Multiple Myeloma Open-Label, Multicenter, Single Ascending Dose Study to Assess the Safety of P-BCMA-101 in Subjects with Relapsed/Refractory Multiple Myeloma (MM) Followed by a Phase 2 Assessment of Response and Safety (PRIME) Active, not recruiting
UCSD Aivita Ovarian and Fallopian Tube Carcinoma Autologous Dendritic Cells Loaded With Autologous Tumor Associated Antigens for Treatment of Advanced Epithelial Ovarian Carcinomas Active, not recruiting
UCSD Fate Therapeutics Solid tumors FATE-NK100 as Monotherapy and in Combination with Monoclonal Antibody in Subjects with Advanced Solid Tumors Active, not recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Study Evaluating KTE-C19 in Combination With Atezolizumab in Subjects With Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (ZUMA-6) No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
ImmunoCellular Therapeutics Cancer - Brain A Phase 3 Randomized Double-blind, Controlled Study of ICT-107 With Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu

SanBio Stroke Study of Modified Stem Cells in Patients With Chronic Motor Deficit From Ischemic Stroke No longer active
UCLA
Kit L Shaw, PhD
(310) 267-0584
kshaw@mednet.ucla.edu
UCLA Severe Combined Immunodeficiency (SCID) Autologous Transplant of EFS-ADA Modified Bone Marrow Cells for ADA-Deficient Severe Combined Immunodeficiency (SCID) No longer active
UCSD UCSD Cancer - Leukemia UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia No longer active
UCI
UCI Stem Cell Clinic
(949) 824-3990
stemcell@uci.edu
jCyte Eye - Retinitis Pigmentosa (RP) Safety of a Single, Intravitreal Injection of Human Retinal Progenitor Cells (jCell) in Retinitis Pigmentosa No longer active
UCLA
Maricela Gonzalez
(310) 557-3729
mmgonzalez@mednet.ucla.edu
Calimmune HIV/AIDS Safety Study of a Dual Anti-HIV Gene Transfer Construct to Treat HIV-1 Infection No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Study Evaluating the Efficacy and Safety of JCAR015 in Adult B-cell Acute Lymphoblastic Leukemia (B-ALL) No longer active
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Leukemia Long-Term Follow-up Study for Patients Previously Treated With JCAR015 No longer active
UCSD UCSD Cancer - Leukemia Extension Study of UC-961 (Cirmtuzumab) for Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961 No longer active
UCSD Asterias Biotherapeutics Spinal Cord Injury Dose Escalation Study of AST-OPC1 in Spinal Cord Injury No longer active
UCLA
Sarah Larson, MD
310-206-8477
slarson@mednet.ucla.edu
UCLA Cancer TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma (NYSCT MM) No longer active
UCSD
UCSD Stem Cell Clinic
(844) 317-7836
alphastemcellclinic@ucsd.edu
Persimmune, Inc. Cancer - Blood Collection of Bone Marrow, Peripheral Blood (PB), Epithelial Tissue, and Saliva Samples From Patients With Myelodysplastic Syndromes (MDS) to Identify MDS-Specific Antigens No longer active
UCSD Persimmune, Inc. Cancer - Blood Personalized Adoptive Cellular Therapy Targeting MDS Stem Cell Neoantigens (PACTN) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Capricor Therapeutics Muscle - Duchenne Muscular Dystrophy A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (HOPE-2) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Nohla Therapeutics Cancer – Leukemia Phase 2 open-label, multi-center, randomized, controlled, dose-finding study of safety and efficacy of NLA101 to reduce the rate of infections associated with CIN in adult subjects with AML No longer active
UC Davis
Jane McCluskepy
916-703-9302
jmccluskey@ucdavis.edu
Medeor Therapuetics Kidney Transplant Cellular Immunotherapy in Recipients of HLA-matched, Living Donor Kidney Transplants No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Kite Pharma Advanced Cancer A Study Evaluating the Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Subjects with Advanced Cancers No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@ucdavis.edu
Atara Bio. EBV-PTLD Multicenter, Open Label, Phase 3 Study of Tabelecleucel for Solid Organ Transplant Subjects with Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure of Rituximab or Rituximab and Chemotherapy (ALLELE Study) No longer active
City of Hope
Erminia Massarelli, MD
626-218-9200
emassarelli@coh.org
Atara Bio. Cancer - Nasopharyngeal Carcinoma Tabelecleucel in Combination With Pembrolizumab in Subjects With Epstein-Barr Virus-associated Nasopharyngeal Carcinoma (EBV+ NPC) No longer active
UC Davis
Jane McCluskey
916-703-9302
jmccluskey@hotmail.com
Capricor Therapeutics COVID A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Delivery of CAP-1002 in Patients with Severe COVID-19 No longer active
City of Hope & UCLA
City of Hope: Amrita Krishnan, MD
(626) 256-4673 ext 62405
AKrishnan@coh.org

UCLA: Maricella Gonzalez
310-557-3729
mmgonzalez@mednet.ucla.edu
City of Hope HIV/AIDS Safety Study of Zinc Finger Nuclease CCR5-modified Hematopoietic Stem/Progenitor Cells in HIV-1 Infected Patients Recruiting
City of Hope
Jana Portnow, MD
(626) 256-4673 ext 62909
jportnow@coh.org
City of Hope Cancer - Brain Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas Recruiting
City of Hope
Behnam Badie, MD
(626) 256-4673 ext 60098
bbadie@coh.org
City of Hope Cancer - Brain Genetically Modified T-cells in Treating Patients With Recurrent or Refractory Malignant Glioma Recruiting
City of Hope
L. Elizabeth Budde, MD, PhD
(626) 256-4673
ebudde@coh.org
City of Hope Cancer - Leukemia Genetically Modified T-cell Immunotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung A Phase I/II Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Subjects With Stage IIIb or Stage IV Non-Small Cell Lung Cancer (NSCLC) Recruiting
City of Hope
Karen Reckamp, MD
(626) 256-4673 x89200
kreckamp@coh.org
Adaptimmune Cancer - Lung Screening Protocol for Tumor Antigen Expression and HLA Sub-Type in NSCLC Recruiting
City of Hope
Mihaela Cristea, MD
(626) 256-4673 x89200
mcristea@coh.org
Adaptimmune Cancer - Ovarian A Phase I/IIa, Open Label Clinical Trial Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs Specific for NY-ESO-1 in Patients With Recurrent or Treatment Refractory Ovarian Cancer. Recruiting
City of Hope
Nadia Ewing, MD
(626) 256-4673 x89200
​newing@coh.org
Sangamo Therapeutics Hemophilia B Ascending Dose Study of Genome Editing by the Zinc Finger Protein (ZFP) Therapeutic SB-FIX in Subjects With Severe Hemophilia B Recruiting
City of Hope
Cara Nolan
626-256-4673 ext 32341
cnolan@coh.org
Juno Therapeutics Cancer - Lymphoma Study Evaluating the Safety and Pharmacokinetics of JCAR017 in B-cell Non-Hodgkin Lymphoma (NHL) Recruiting
City of Hope
Hormoz Mirshkarlo
626-218-8074
hmirshkarlo@coh.org
Kite Pharma Cancer - Lymphoma A Phase 1-2 Multi-Center Study Evaluating KTE-C19 in Subjects With Refractory Aggressive Non-Hodgkin Lymphoma (ZUMA-1) (ZUMA-1) Recruiting
City of Hope
Erminia Massarelli
626-218-9200
emassarelli@coh.org
Tessa Therapeutics Cancer - Nasopharyngeal Carcinoma A Multicentre, Randomized, Open-Label, Phase III Clinical Trial Of Gemcitabine And Carboplatin Followed By Epstein-Barr Virus-Specific Autologous Cytotoxic T Lymphocytes Versus Gemcitabine And Carboplatin As First Line Treatment For Advanced Nasopharyngea Recruiting
1 2 3

Clinical trials conducted at CIRM Alpha Stem Cell Clinics must comply with applicable federal and state laws and medical and ethical standards governing the conduct of human clinical trials. If you or a family member is interested in participating in a clinical trial, please visit clinicaltrials.gov to find a trial near you.

Find Out More:
About Alpha Stem Cell Clinics
Alpha Clinics News